Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Povorcitinib in Renal Impairment
NCT05624723Phase 1Completed
- Sponsor
- Incyte
- Start
- Jan 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of povorcitinib in hidradenitis suppurativa (HS), Vitiligo and prurigo nodularis (PN) (5 arms), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration and 1 more. Started Jan 2023; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)Vitiligoprurigo nodularis (PN)
Beyond the preview
Go deeper on NCT05624723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624723.